Compare Regeneron Pharmaceuticals Inc (REGN) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Williams-Sonoma, Inc. trades at $239 (market cap $28.15B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.7× Williams-Sonoma, Inc.'s market cap, and Williams-Sonoma, Inc. pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Williams-Sonoma, Inc. for 59 Days on average.
| REGN | WSM | |
|---|---|---|
Market Cap | $76.14B | $28.15B |
Volume | 500,239 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $251.81 |
52-Week Low | $557.73 | $168.64 |
Typical Hold Time | 107 Days | 59 Days |
Enterprise Value | $70.85B | $28.65B |
Dividend Yield | 0.51% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical signal and strong profitability metrics. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights market share gains, margin expansion, and new store openings, reinforcing positive business momentum.
The outlook remains favorable given earnings outperformance and raised guidance, though valuation multiples are elevated. Key risks include housing market sensitivity and competitive pressures. Analyst consensus is mixed but leans positive, with a price target suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
